TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3028663

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy with VP 16, ifosfamide, vindesine (VPIV), adriamycin, cisplatinum, vincristine (APO), and cyclophosphamide, methotrexate, CCNU (CMCC)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Cisplatinum/VP 16 (PVP)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ifosfamide/VP 16 (IVP)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard treatment with ACO (adriamycin, cyclophosphamide, vincristine)
Number of subjects: 450
Study: 30551334

Group type: EXPERIMENTAL
Intervention: Body psychotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 23
Study: 27030249

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: COMPARATOR
Intervention: Rasagiline 1 mg/day and Placebo
Number of subjects: 170
Study: 25042018

Group type: EXPERIMENTAL
Intervention: Lower household per capita income (quartile 1, 2, 3)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 670

Group type: COMPARATOR
Intervention: Silent cerebral infarct
Number of subjects: 670

Group type: COMPARATOR
Intervention: Painful episodes
Number of subjects: 670
Study: 22419863

Group type: EXPERIMENTAL
Intervention: GSK233705 20 μg + salmeterol 50 μg twice-daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GSK233705 50 μg + salmeterol 50 μg twice-daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Salmeterol 50 μg twice-daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Tiotropium 18 μg once-daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 20413397

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 20323

Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage (ICH)
Number of subjects: 20323

Group type: EXPERIMENTAL
Intervention: Non-ICH major bleeding
Number of subjects: 20323

Group type: EXPERIMENTAL
Intervention: Minor bleeding
Number of subjects: 20323

Group type: EXPERIMENTAL
Intervention: Cardiogenic shock
Number of subjects: 20323

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 20323

Group type: EXPERIMENTAL
Intervention: Age (among 30-day survivors)
Number of subjects: 20323

Group type: EXPERIMENTAL
Intervention: Heart rate (among 30-day survivors)
Number of subjects: 20323
Study: 18701766

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 15714213

Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Hospital discharge
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Vitamin C deficiency
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Folic acid deficiency
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Vitamin E deficiency
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Vitamin B(12) deficiency
Number of subjects: 3310

Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency
Number of subjects: 3310
Study: 12093062

Group type: EXPERIMENTAL
Intervention: Standard therapy with additional multiantioxidant supplementation (Vitamin E and C, Allopurinol, N-acetylcysteine, and mannitol administered perioperatively)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 42
Study: 10617256

Group type: EXPERIMENTAL
Intervention: Calcitonin suppositories (200 IU daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 40
Study: 8803651

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 1442906

Group type: EXPERIMENTAL
Intervention: Conservative surgery and presacral neurectomy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conservative surgery alone
Number of subjects: 71
Study: 6690191

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg intravenous injection followed by 2 mg/h infusion)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30537846

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg/hydrochlorothiazide 12.5 mg
Number of subjects: 12705

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 12705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12705
Study: 29632234

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg or 10 mg)
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Aspirin (100 mg)
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2832
Study: 27722223

Group type: EXPERIMENTAL
Intervention: Immediate loading (within 48 hours)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Early loading (at 6 weeks)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional loading (at 3 months)
Number of subjects: 81
Study: 24786925

Group type: EXPERIMENTAL
Intervention: Abatacept (ABA) treatment
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 22613690

Group type: EXPERIMENTAL
Intervention: Enhanced early communication therapy by speech and language therapists (SL therapy), up to three contacts per week for up to 16 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Attention control (AC) with a similar number of contacts by employed visitors
Number of subjects: 170
Study: 20154405

Group type: EXPERIMENTAL
Intervention: Varenicline (VG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nicotine patch (NG)
Number of subjects: 32
Study: 18804227

Group type: EXPERIMENTAL
Intervention: Initial azoospermic reading (pre-centrifugation)
Number of subjects: 3205
Study: 16172865

Group type: EXPERIMENTAL
Intervention: Dry chamber dives
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Wet chamber dives
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 33
Study: 12057861

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) on days 1 and 8 plus carboplatin 300 mg/m(2) on day 1 (arm B)
Number of subjects: 198

Group type: COMPARATOR
Intervention: cisplatin (CDDP) 70 mg/m(2) on day 1 plus vinblastine (VLB) 6 mg/m(2) on days 1 and 8 (arm A)
Number of subjects: 198
Study: 10048518

Group type: EXPERIMENTAL
Intervention: Ulnar nerve block with mepivacaine HCI injection
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Median nerve block with mepivacaine HCI injection
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combined ulnar and median nerve block
Number of subjects: 21

Group type: COMPARATOR
Intervention: Preinjection strength
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ulnar nerve block
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Median nerve block
Number of subjects: 21
Study: 7734353

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: b3a2 transcript subgroup with presenting white-cell count < 100 x 10(9)/l
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: b2a2 transcripts
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Genomic breakpoint site or BCR/ABL RNA transcript
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Cytogenetic response
Number of subjects: 234
Study: 1889319

Group type: EXPERIMENTAL
Intervention: PGI2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-molecular-weight Dextran
Number of subjects: 18
Study: 6689424

Group type: EXPERIMENTAL
Intervention: Cyclic combination chemotherapy of mustine, vinblastine, prednisolone, and procarbazine (MVPP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total nodal irradiation (TNI)
Number of subjects: 60
Study: 30635072

Group type: EXPERIMENTAL
Intervention: Telephone assistance to quit smoking (including psychological and psychoeducational support, and pharmacological treatment advice if required) for 12 months
Number of subjects: 510

Group type: COMPARATOR
Intervention: Brief advice after discharge
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Telephone assistance to quit smoking
Number of subjects: 510
Study: 29795207

Group type: EXPERIMENTAL
Intervention: Diarrhoea at admission
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lack of appetite
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Suspected sepsis
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Skin ulcers
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Chest indrawing
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Oxygen saturation below 94%
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Confirmed HIV infection
Number of subjects: 400
Study: 27274715

Group type: EXPERIMENTAL
Intervention: MaxxTOR® (MT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 18
Study: 24810684

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training program (8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 36
Study: 22227587

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAART use among IDUs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAART delivery to IDUs
Number of subjects: 0
Study: 19159075

Group type: EXPERIMENTAL
Intervention: 0.02% epinephrine (10 ml)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Saline (control group, 10 ml)
Number of subjects: 370
Study: 17673583

Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee replacement
Number of subjects: 174

Group type: COMPARATOR
Intervention: Fixed-bearing total knee replacement
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 174
Study: 15705725

Group type: EXPERIMENTAL
Intervention: Submaximal voluntary contractions at 30% of maximal voluntary contraction
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isometric reference contractions
Number of subjects: 17
Study: 11817908

Group type: EXPERIMENTAL
Intervention: Lipids 20% energy diet + educational program (EP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lipids 30% energy diet (control group)
Number of subjects: 80
Study: 10439009

Group type: EXPERIMENTAL
Intervention: Patients with azoospermia (n = 40)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with Sertoli cell‐only syndrome (n = 36)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (proven fathers n = 14 and healthy women n = 4)
Number of subjects: 40
Study: 7541358

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) 100 mg/day for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) 100 mg/day for 4 weeks
Number of subjects: 0
Study: 2087410

Group type: EXPERIMENTAL
Intervention: APF foam application
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: APF gel application
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sponge-lined trays
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Unlined trays
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: First appointment with unlined trays
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Second appointment with unlined trays
Number of subjects: 59
Study: 6106736

Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 64
Study: 31999048

Group type: EXPERIMENTAL
Intervention: Cyberball exclusion paradigm
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cyberball overinclusion paradigm
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study: 29236526

Group type: EXPERIMENTAL
Intervention: Full-color graphic warning labels (GWLs)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Black-and-white graphic warning labels (GWLs)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Graphic warning labels (either color or black-and-white)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Text-only labels
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Graphic warning labels and text-only labels
Number of subjects: 653

Group type: COMPARATOR
Intervention: Brand imagery only
Number of subjects: 653
Study: 27321197

Group type: COMPARATOR
Intervention: Glasses with power determined by subjective cycloplegic retinoscopy by a university optometrist (U)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Ready-made spectacles (RM)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Glasses with power determined by a rural refractionist (R)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Glasses with power determined by non-cycloplegic self-refraction (SR)
Number of subjects: 426
Study: 25793635

Group type: EXPERIMENTAL
Intervention: Binaural monopolar galvanic vestibular stimulation (GVS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 7
Study: 24512246

Group type: EXPERIMENTAL
Intervention: Social Anxiety Disorder (SAD) group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 86
Study: 22440336

Group type: EXPERIMENTAL
Intervention: Tivantinib plus erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 0
Study: 19352169

Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 101

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 101
Study: 17898251

Group type: COMPARATOR
Intervention: i.v. fentanyl citrate (1.5 microg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl citrate (3.0 microg/kg)
Number of subjects: 41
Study: 15115681

Group type: EXPERIMENTAL
Intervention: sulphur baths
Number of subjects: 40

Group type: COMPARATOR
Intervention: control group (spa therapy alone)
Number of subjects: 40
Study: 11641670

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 microg)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Intravenous oxytocin (20 units)
Number of subjects: 325
Study: 9853762

Group type: EXPERIMENTAL
Intervention: Triptorelin depot treatment for 12 weeks before hysterectomy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 127
Study: 8003098

Group type: EXPERIMENTAL
Intervention: Sitostanol esters (< 1 g/day of free sterols) dissolved in rapeseed oil (RSO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RSO diet (control group)
Number of subjects: 0
Study: 2786179

Group type: EXPERIMENTAL
Intervention: 100 Hz, 250 msec TENS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 Hz, 50 msec TENS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pain suppressor TENS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 Hz, 250 msec TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pressure algometer assessment
Number of subjects: 60
Study: 1118088

Group type: EXPERIMENTAL
Intervention: Diuril, 500 mg/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dilantin, 100 mg, t.i.d.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no drugs)
Number of subjects: 75
Study: 31825926

Group type: EXPERIMENTAL
Intervention: Li‐ESWT treatment (4 sessions on the PiezoWave2 unit)
Number of subjects: 60
Study: 30252774

Group type: EXPERIMENTAL
Intervention: HIGH (1.83 g protein·kg·d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MOD (1.20 g protein·kg·d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LOW (0.94 g protein·kg·d)
Number of subjects: 10
Study: 27761704

Group type: EXPERIMENTAL
Intervention: Limbal conjunctival autograft (LCAG) with intraoperative 0.02% mitomycin C (MMC) for 3 min
Number of subjects: 96

Group type: COMPARATOR
Intervention: Amniotic membrane graft (AMG) with intraoperative 0.02% mitomycin C (MMC) for 3 min
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Limbal conjunctival autograft (LCAG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Amniotic membrane graft (AMG)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 25630442

Group type: EXPERIMENTAL
Intervention: Positive interaction between Agents A and B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B hitting Agent C while A was absent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A witnessing B's harmful action
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B accidentally hitting C while A was present
Number of subjects: 0
Study: 21593284

Group type: EXPERIMENTAL
Intervention: Project Wings Girls' Groups (16-session facilitated curriculum including sharing circles, mind-body exercises, and coping skills building)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Attention control (similar format but focused on general health topics)
Number of subjects: 42
Study: 22168590

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (hemoglobin threshold of 10 g/dL)
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (hemoglobin level <8 g/dL or symptoms of anemia at physician discretion)
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 2016
Study: 19917850

Group type: EXPERIMENTAL
Intervention: Induction biochemotherapy (cisplatin, vinblastine, dacarbazine, decrescendo IL-2, interferon alfa-2b, GM-CSF)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Maintenance biotherapy (low-dose IL-2 and GM-CSF followed by intermittent pulses of decrescendo IL-2 over 12 months)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: CNS progression
Number of subjects: 133
Study: 16825703

Group type: EXPERIMENTAL
Intervention: Concentrated red grape juice (RGJ) 100 mL/d for 14 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Concentrated red grape juice (RGJ) for 3 weeks in hemodialysis patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (12 hemodialysis patients not receiving RGJ)
Number of subjects: 41
Study: 15273015

Group type: EXPERIMENTAL
Intervention: Self and close others
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal closeness
Number of subjects: 0
Study: 11404812

Group type: EXPERIMENTAL
Intervention: Specific and high goal
Number of subjects: 109

Group type: COMPARATOR
Intervention: Do your best goal
Number of subjects: 109
Study: 9060852

Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Low‐flow cardiopulmonary bypass (LFB)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: EEG seizures
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Factors associated with EEG seizures
Number of subjects: 171
Study: 8351678

Group type: EXPERIMENTAL
Intervention: Gastro‐Intestinal‐Therapeutic‐Systems (GITS) 2.5 mg (Treatment B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gastro‐Intestinal‐Therapeutic‐Systems (GITS) 5 mg (Treatment C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immediate release tablets (3 x 1 mg) (Treatment A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional sustained release formulation (4 mg) (Treatment D)
Number of subjects: 24
Study: 3826577

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Meptazinol
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Both groups (Pethidine and Meptazinol)
Number of subjects: 1100
Study: 30045702

Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation condition (active therapy control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care risk reduction counseling
Number of subjects: 0
Study: 27064671

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isotonic saline injections
Number of subjects: 9
Study: 24039182

Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate (EGCG), a DYRK1A inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGCG
Number of subjects: 0
Study: 22183086

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,000 IU/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation and Placebo (combined)
Number of subjects: 23
Study: 20508467

Group type: EXPERIMENTAL
Intervention: Weight+plyometrics+EMS (EP)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Weight+plyometrics (VP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29
Study: 18448328

Group type: COMPARATOR
Intervention: FUOX (fluorouracil/oxaliplatin)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Favorable genotypes (0, 1, or 2 FG)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Favorable genotypes (2 FG)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ERCC1-118
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: TS-3'UTR
Number of subjects: 110
Study: 16979511

Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dry-towel massage
Number of subjects: 33

Group type: COMPARATOR
Intervention: Presence
Number of subjects: 33
Study: 14513919

Group type: EXPERIMENTAL
Intervention: Paroxetine coadministered with clonazepam followed by a tapered benzodiazepine discontinuation phase (PC-D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ongoing combination treatment (PC-M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paroxetine and placebo (PP)
Number of subjects: 60
Study: 11069324

Group type: EXPERIMENTAL
Intervention: Quadruple therapy of TDB 240 mg b.d., furazolidone 100 mg b.d., josamycin 1000 mg b.d. and famotidine 20 mg b.d. (BFJF group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Triple therapy of TDB 240 mg b.d., furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. (BFC group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (BFJF group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Triple therapy (BFC group)
Number of subjects: 120